Targeting Two Types of Lymphoma
The FDA granted accelerated approval to the molecularly targeted therapeutic umbralisib for certain patients with marginal zone lymphoma or...
Progress Against Cancer
The FDA granted accelerated approval to the molecularly targeted therapeutic umbralisib for certain patients with marginal zone lymphoma or...
The FDA granted accelerated approval to a new oral targeted therapeutic to treat certain adult patients with the most...
The FDA approved the combination of an immune checkpoint inhibitor and a therapeutic that prevents tumors from growing blood...
The FDA approved a molecularly targeted therapeutic for treating certain patients with some rare cancers affecting the gastrointestinal system. The U.S. Food and...
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form...
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a...
The FDA has approved a new targeted therapeutic for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies....
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with...
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer...